Status:
UNKNOWN
18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Conditions:
18F-HER2 PET
Eligibility:
All Genders
30-80 years
Phase:
NA
Brief Summary
This is a open-label, one-arm, multicenter study aimed to explore the efficacy and safety of 18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.
Eligibility Criteria
Inclusion
- Informed consent document must be signed.
- Aged 30-80 years old, both genders.
- Patients with locally advanced or advanced urothelial carcinoma
- Patients plan to undergo anti HER2 treatment.
Exclusion
- Subjects with active malignancies other than urothelial carcinoma within 5 years should be excluded.
- Patients with severe liver, kidney, and hematopoietic diseases
- Patients with other mental disorders or primary emotional disorders
- Those who are unable to understand, comply with the research protocol, or sign an informed consent form
- PET imaging Contraindication (including pregnant women, lactating women, women of childbearing age who have a recent fertility plan, etc.)
- Individuals who are allergic to imaging agents
- Hypoglycemic reactions, severe pain, etc. cannot be accompanied by PET scans
Key Trial Info
Start Date :
August 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05983796
Start Date
August 10 2023
End Date
September 30 2025
Last Update
August 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital, Zhejiang University School of medicine
Hangzhou, Zhejiang, China, 310009